Search research articles
Contact Us
Filters
Showing results (51-60 of 123) with videos related to
Page
of 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2005
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer
Anthony W Tolcher, Kim Chi, John Kuhn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2005
Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors
Alejandro D Ricart, Lisa A Hammond, John G Kuhn, et al.
Cancer Chemotherapy and Pharmacology
|
February 28, 2008
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
Jordi Rodon, Mitchell Garrison, Lisa A Hammond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2004
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study
Emiliano Calvo, Anthony W Tolcher, Lisa A Hammond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas
James A Posey, M Wasif Saif, Ronda Carlisle, et al.
Investigational New Drugs
|
March 1, 2016
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
Jeffrey R Infante, David S Mendelson, Howard A Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2011
Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin
Anthony W Tolcher, Christopher J Sweeney, Kyri Papadopoulos, et al.
Journal for Immunotherapy of Cancer
|
February 6, 2023
Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors
Anthony W Tolcher, Michael Gordon, Kathleen M Mahoney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 26, 2006
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors
Amita Patnaik, Debra Wood, Anthony W Tolcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2016
A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors
Emiliano Calvo, Jean-Charles Soria, Wen Wee Ma, et al.
Page
of 13
Search research articles
Search
Showing results (51-60 of 123) with videos related to
Sort By:
Page
of 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2005
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer
Anthony W Tolcher, Kim Chi, John Kuhn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2005
Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors
Alejandro D Ricart, Lisa A Hammond, John G Kuhn, et al.
Cancer Chemotherapy and Pharmacology
|
February 28, 2008
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
Jordi Rodon, Mitchell Garrison, Lisa A Hammond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2004
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study
Emiliano Calvo, Anthony W Tolcher, Lisa A Hammond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas
James A Posey, M Wasif Saif, Ronda Carlisle, et al.
Investigational New Drugs
|
March 1, 2016
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
Jeffrey R Infante, David S Mendelson, Howard A Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2011
Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin
Anthony W Tolcher, Christopher J Sweeney, Kyri Papadopoulos, et al.
Journal for Immunotherapy of Cancer
|
February 6, 2023
Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors
Anthony W Tolcher, Michael Gordon, Kathleen M Mahoney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 26, 2006
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors
Amita Patnaik, Debra Wood, Anthony W Tolcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2016
A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors
Emiliano Calvo, Jean-Charles Soria, Wen Wee Ma, et al.
Page
of 13